Antitumor T-cell frequency within metastases collected before and after treatment in patient CIP-5
| T cells . | Before treatment . | After treatment . |
|---|---|---|
| Anti–MAGE-3.A26* | < 0.00075% | 0.04% |
| Anti–MAGE-3.B44* | < 0.00075% | 0.00074% |
| Anti–MelanA/MART-1.A2 | 0.0015% | 0.00158% |
| Anti–MelanA/MART-1.A26 | < 0.00075% | 0.0041% |
| Anti–MAGE-1.A26 | nd | nd |
| Other antitumor | 0.02% | 0.022% |
| T cells . | Before treatment . | After treatment . |
|---|---|---|
| Anti–MAGE-3.A26* | < 0.00075% | 0.04% |
| Anti–MAGE-3.B44* | < 0.00075% | 0.00074% |
| Anti–MelanA/MART-1.A2 | 0.0015% | 0.00158% |
| Anti–MelanA/MART-1.A26 | < 0.00075% | 0.0041% |
| Anti–MAGE-1.A26 | nd | nd |
| Other antitumor | 0.02% | 0.022% |
nd indicates not determined.
Antivaccine T cells.